Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma

Laura Amanda Vallejo-Aparicio¹ · Jesús Molina² · Iñigo Ojanguren^{3,4} · Ana Viejo Casas⁵ · Alicia Huerta¹ · Henrik Svedsaeter⁶

Published online: 4 December 2019
 © Springer-Verlag GmbH Germany, part of Springer Nature 2019

Correction to: The European Journal of Health Economics
<https://doi.org/10.1007/s10198-019-01101-x>

In the published article, the Table 1 was published incorrectly.

The correct Table 1 is given below

Variables	FF/VI 184/22 mcg and 92/22 mcg	UC group
Monthly drug costs [17, 21]	€51.52 ^a	ICS = €18.75 ^b ICS/LABA = €48.25 ^b
Annual drug costs (€, 2018)	€627.26	€557.31
Asthma management direct annual costs (€, 2018) ^c [19, 20]		
Uncontrolled (ACT score ≤ 15)	€1919.01	
Partially controlled (ACT score 16–19)	€1015.61	
Well-controlled (ACT score ≥ 20)	€656.90	

The original article can be found online at <https://doi.org/10.1007/s10198-019-01101-x>.

✉ Laura Amanda Vallejo-Aparicio
laura.a.vallejo@gsk.com

- 1 Market Access, GSK (GlaxoSmithKline), Madrid, Spain
- 2 Centro de Salud Francia, Fuenlabrada, Madrid, Spain
- 3 Servicio de Neumología, Hospital Universitario Vall d'Hebron, Barcelona, Spain
- 4 Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain
- 5 Centro de Salud Pisueña Cayon, Cantabria, Spain
- 6 Value Evidence and Outcomes, GSK, Brentford, UK

Variables	FF/VI 184/22 mcg and 92/22 mcg	UC group
Assumed proportion of days covered, %	100	100
Assumed current uptake, %	10	90
Assumed new uptake, %	20	80
Percentage of subjects in each ACT category (ITT population, n = 4233) [18]		
Baseline		
Uncontrolled	41%	41%
Partially controlled	31%	31%
Well-controlled	28%	28%
24 weeks		
Uncontrolled	20%	29%
Partially controlled	20%	25%
Well-controlled	60%	46%
52 weeks		
Uncontrolled	21%	30%
Partially controlled	20%	26%
Well-controlled	59%	44%

FF/VI fluticasone furoate/vilanterol, ICS inhaled corticosteroid, ICS/LABA inhaled corticosteroid/long-acting beta-agonist, ACT Asthma Control Test, ITT intention-to-treat

^aPrice to Public plus VAT of FF/VI 184/22 and 92/22 mcg

^bUC cost calculated as a weighted average drug cost of all available presentations at Price to Public plus VAT

^cCosts annualised at updated to 2018